Loading...
Dear E, Will you be at the J.P. Morgan Healthcare Conference next month? If so, please join us for the FierceBiotech Executive Breakfast & Panel Discussions on January 14th at the Fairmont Hotel in San Francisco. This year's event will feature a full breakfast buffet, two panel discussions, coffee break, and an Ask the Experts Closing Reception. During Panel One, Strategic Considerations for the Commercialization of Cell and Gene Therapies, we will speak to key leaders and discuss the challenges to commercializing cell-based and gene therapies, as well as explore how drugmakers are leveraging emerging technologies to meet production requirements, maximize efficiency, and track patients’ progress for performance-based payment deals. Speakers include: Dr. Mitchell Finer / Chief Scientific Officer / ElevateBio David J. Lennon, Ph.D. / President / AveXis, a Novartis Company Paul Levesque / Global President of Pfizer Rare Disease / Pfizer Opening Remarks: Keiko Oishi / President and COO / CMIC Alberto Santagostino / Head of Cell and Gene Technologies / Lonza Closing Remarks: Stephen J. Ubl / President and Chief Executive Officer / PhRMAPanel Two, The Promise of AI: Can Artificial Intelligence and Machine Learning Really Transform R&D?, will discuss how drug discovery is one area where AI systems can revolutionize the process of R&D. By applying these tools to patient data, from genomics to electronic health records, researchers can gain deeper insights into the populations they’re ultimately trying to treat. Speakers include: Seats are limited and expected to sell out. Early Bird Rates end next Friday, December 13th - click here to register and reserve your spot at the event. I look forward to seeing you in San Francisco. Best, Rebecca Willumson |
Click here to unsubscribe or to manage your subscriptions. ©2019 FierceMarkets, a division of Questex, LLC. All rights reserved. 1900 L St NW | Washington, DC | 20036 www.questex.com |
Loading...
Loading...